Articles related to DEPRESSION

This meta analysis of antidepressants in MDD included 34 double-blind, randomized, placebo-controlled studies covering 20 antidepressants. Outcomes were 6-month relapse rates and tolerability measures. Fourteen of the agents had better relapse rates than placebo. Four — desvenlafaxine, paroxetine, venlafaxine, and vortioxetine — displayed the best efficacy and tolerability.

“Because medicine abhors a therapeutic vacuum,” the hallucinogens psilocybin and LSD are being revisited as potential candidates for treating depression. But effect size seems less than that of currently approved antidepressants.

In this phase 2 double-blind trial, adults with treatment-resistant depression were randomly assigned to receive psychological support and a single dose of a proprietary, synthetic form of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control). The Montgomery-Sberg Depression Rating Scale (MADRS) total score change from baseline to week three was the main outcome measure. Secondary endpoints included remission at week 3, response at week 3, and sustained response at 12 weeks.

This overview and discussion highlights the learnings gleaned during practice in a ketamine service unit. Discussion points include treatment considerations for the two entities, switching from IV to intranasal, and a collection of pearls.

The way that physician burnout is currently framed contributes to misconceptions about and stigma surrounding depression and discourages us from fully utilizing the resources available to prevent and treat depression.

Bupropion inhibits cytochrome P450 2D6,5 which is the enzyme that converts venlafaxine into an active metabolite, desvenlafaxine. When CYP2D6 is inhibited, venlafaxine levels rise at the expense of desvenlafaxine. Because the renal excretion of venlafaxine is small, the consequence is increased dose-dependent venlafaxine-related adverse effects.